Page 9 - Ocular Hypertension News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Primary Biliary Cholangitis Market to surge at 16 37% CAGR, driven by increasing prevalence and expected launch of novel therapies during the forecast period (2017-2030), affirms DelveInsight

Primary Biliary Cholangitis Market to surge at 16 37% CAGR, driven by increasing prevalence and expected launch of novel therapies during the forecast period (2017-2030), affirms DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomShruti thakurZydus cadilaDelveinsight trichotillomaniaPrnewswire delveinsightMarket companiesDrug administrationMarket researchIntercept pharmaceuticalsDelveinsight business researchBiliary cholangitisPrimary biliary cholangitisPrimary biliaryCymabay therapeuticsCara therapeutics

Novel Rheumatoid Arthritis drugs succeed in the clinical trials: A status report by DelveInsight

Novel Rheumatoid Arthritis drugs succeed in the clinical trials: A status report by DelveInsight
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLos angelesGenor biopharmaAstellas pharmaBristol myers squibbGilead sciencesUniversity collaborations licensing partnering rheumatoid arthritis analysisRheumatoid arthritis key companiesRoute of administrationRheumatoid arthritisRheumatoid arthritis pipelineOryn therapeuticsSorrento therapeuticsKang stem biotechCelltex therapeuticsTaisho pharmaceutical

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaScott corningRabia gurses ozdenAntony mattessichDonald notmanMichael goldsteinChris brinzeyRegeneron pharmaceuticalsDrug administrationKey program updatesHorizons forumOcular therapeutix incExchange commissionAmerican medical associationClinical development

Indoco announces launch of Brinzolamide Ophthalmic Suspension 1% in U S

The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa. The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye. The US market size of this product is $184 million, according to IQVIA data as of December, 2020. Powered by Capital Market - Live News (This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,

United statesDrug administration for brinzolamide ophthalmic suspensionTeva pharmaceuticalsIndoco remediesBrinzolamide ophthalmic suspensionDrug administrationOphthalmic suspensionCapital marketOrganic compoundsFunctional groupsCarbonic anhydrase inhibitorsGeneric drugTeva canadaPharmaceuticals necOcular hypertensionஒன்றுபட்டது மாநிலங்களில்